Eli Lilly’s Dan Skovronsky on oral GLP-1, ‘slower ramp’ for Alzheimer’s and deals on ‘underappreciated’ assets
Dan Skovronsky knows that any conversation about Eli Lilly is going to be largely about its work in obesity and Alzheimer’s. Although he wants everyone to know that the company is also excited about candidates in immunology and oncology, he’s also ready to take questions about those hottest topics head-on.
Speaking at an investor conference organized by Evercore ISI, Skovronsky — whose string of titles at Lilly includes executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories — addressed both high-level and granular questions about the pipeline and strategy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
